Merck gets saci in ovarian
Sacituzumab tirumotecan joins raludotatug deruxtecan on the ovarian cancer pivotal stage.
Private US biotechs head for human trials
Halda, Accent and Vividion take more projects into phase 1.
Jabez heads for the clinic
JBZ-001, acquired last year, features with CD-001 and ADCE-D01 among recent clinical trial entrants.
AstraZeneca doubles down on GPC3
The company takes its T-cell engager into the clinic, just as Roche and Sanofi exit.
Pivotal study designs revealed
Keenly awaited trials of ficerafusp alfa, Trodelvy and divarasib materialise.
NextCure joins the B7-H4 brigade
Meanwhile, Olema’s KAT6 inhibitor will take on rival projects from Pfizer and Menarini.
